Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.

ABSTRACT: Chagas disease following infection with Trypanosoma cruzi is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the migration of infected individuals. The currently available anti-parasitic drugs, nifurtimox and benznidazole, remain insufficiently evaluated for their efficacy in adult patients. A key challenge is the lack of markers for parasitological cure, which also precludes the development of new treatments. Consequently, there is a critical need for a practical method to assess drug performance within a short timeframe. In this retrospective analysis of the phase 2 randomized controlled BENDITA trial (ClinicalTrials.gov: NCT03378661), we report the potential of a serological multiplex method (MultiCruzi), combined with advan

SUBMITTER: Saade U 

PROVIDER: S-EPMC11615370 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature